PHIO

Phio Pharmaceuticals Corp. (PHIO) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.4 (Weak)

PHIO lacks disclosed 5-year revenue, EPS, or FCF CAGR data, limiting evidence of repeatable compounding versus peers with proven multi-year growth histories.

Near-zero EV-to-sales and extremely low EV-to-EBITDA imply the market prices minimal operating scale, consistent with weaker long-term revenue expansion capacity than peers.

Negative ROIC indicates capital deployed has not yet generated durable incremental returns, reducing reinvestment capacity for self-funded growth relative to profitable peers.

Zero reported R&D-to-revenue in the provided metrics suggests limited visible internal growth investment, constraining product or pipeline expansion versus research-intensive peers.

Market Tailwinds

Score:

No peer-relative evidence of sustained demand acceleration is provided, so PHIO cannot be shown to benefit from durable market tailwinds versus better-positioned peers.

The absence of segment concentration data prevents proof of scalable niche leadership, leaving growth visibility weaker than peers with clearer end-market traction.

Negative free-cash-flow yield and negative ROIC indicate the current operating model is not yet converting market opportunity into compounding revenue at peer-like efficiency.

Without disclosed historical growth metrics, the company’s long-term demand capture remains unproven compared with peers that have demonstrated multi-year expansion.

Scalability Expansion

Score:

The provided metrics do not show operating leverage or expanding returns, so incremental revenue scaling appears less efficient than peers with proven margin expansion.

Negative ROIC and minimal valuation multiples suggest the business has not yet demonstrated a scalable economic engine capable of compounding revenue over time.

Capex intensity is effectively negligible, which may preserve cash but also signals limited visible infrastructure for scaling versus peers investing for expansion.

No evidence of durable cash generation or share-count discipline is provided, reducing confidence that growth can be reinvested and compounded internally.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint, because it limits the company’s ability to fund expansion internally and compounds slower than profitable peers.

Missing 5-year growth and margin history creates a visibility constraint, making it harder to evidence durable scaling versus peers with established operating records.

The absence of meaningful operating cash generation in the supplied metrics suggests external financing may remain necessary, which can dilute long-term compounding capacity.

Very small valuation ratios imply the market expects limited scale, and that expectation typically reflects weaker peer-relative growth durability rather than temporary volatility.

Overall Score

Score:

PHIO shows weak 10-year growth potential because the supplied metrics do not evidence durable revenue compounding, scalable reinvestment, or peer-relative operating efficiency.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Phio Pharmaceuticals Corp.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →